Recently, Roth Capital's Michael Higgins reiterated a 'buy' rating on shares of Intec Pharma Ltd. (NASDAQ:NTEC) alongside a price target of $9.50 per share. With an analyst average price target of $12.25 per share, Higgins' price target is the lowest out of the analysts we track that cover NTEC.
With a last trade price of $9.08 for shares of NTEC, this price target represents almost 5% potential upside.
Be sure to subscribe to one or more of our free e-mail newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.